HCA EVP Cuffe disposes of 1,500 company shares

HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported two transactions in HCA common stock on February 3, 2026.

Filing Impact

(Very High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported two transactions in HCA common stock on February 3, 2026. A transaction coded “S” showed the disposition of 1,500 shares at $498.0901 per share. A second transaction coded “G” reported 4,050 shares at $0 per share. After these transactions, he directly owned 25,952.9017 shares of HCA common stock.

Insider Trade Summary

Net Seller: 1,500 shares

Net Sell 2 txns

Insider Cuffe Michael S.

Role EVP and Chief Clinical Officer

Sold 1,500 shs ($747K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,500	$498.0901	$747K
Gift	Common Stock	4,050	$0.00	$0.00

Holdings After Transaction: Common Stock — 25,952.9017 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HCA EVP Michael S. Cuffe report for HCA Healthcare (HCA)?

Michael S. Cuffe reported two HCA Healthcare common stock transactions dated February 3, 2026. One transaction coded “S” disposed of 1,500 shares at $498.0901 per share, and another coded “G” covered 4,050 shares at $0 per share.

How many HCA Healthcare shares did Michael S. Cuffe dispose of in the Form 4 filing?

He reported disposing of 1,500 HCA Healthcare common shares in a transaction coded “S.” The filing shows these shares were disposed of at a price of $498.0901 per share, reducing his directly held position before a second transaction on the same date.

What does the transaction coded "G" involve in Michael S. Cuffe’s HCA Form 4?

The transaction coded “G” involves 4,050 HCA Healthcare common shares reported at a per-share price of $0. This entry appears as a disposition in the table and occurs on the same February 3, 2026 date as the 1,500-share “S” transaction.

How many HCA Healthcare shares does Michael S. Cuffe own after these transactions?

After the reported February 3, 2026 transactions, Michael S. Cuffe directly owns 25,952.9017 HCA Healthcare common shares. This post-transaction balance is listed in the Form 4 table as the amount of securities beneficially owned following the reported activity.

What is Michael S. Cuffe’s role at HCA Healthcare in this Form 4 filing?

In this Form 4, Michael S. Cuffe is identified as an officer of HCA Healthcare. His title is Executive Vice President (EVP) and Chief Clinical Officer, and the form indicates the filing is made by one reporting person in that capacity.

Are Michael S. Cuffe’s HCA Healthcare holdings direct or indirect after the transactions?

The Form 4 shows Michael S. Cuffe’s HCA Healthcare holdings as directly owned after the transactions. The ownership form column lists “D” for direct ownership, with 25,952.9017 common shares beneficially owned following the reported February 3, 2026 activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/05/2026 - 06:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cuffe Michael S.

(Last)

(First)

(Middle)

ONE PARK PLAZA

(Street)

NASHVILLE

37203

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HCA Healthcare, Inc. [ HCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and Chief Clinical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/03/2026		S		1,500	D	$498.0901	30,002.9017	D
Common Stock	02/03/2026		G		4,050	D	$0	25,952.9017	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Kevin A. Ball, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR